Improvements in GORE-TEX® vascular graft performance by Carmeda® BioActive Surface heparin immobilization

European Journal of Vascular and Endovascular Surgery

Volumn 25, Issue 5, 2003, Pages 432-437

  Begovac, P C ^a   Thomson, R C ^a   Fisher, J L ^a   Hughson, A ^a   Gallhagen A ^b  

^a W L GORE AND ASSOCIATES   (United States)

^b Carmeda AB   (Sweden)

Author keywords

ePTFE; Heparin; Patency; Thromboresistance; Vascular graft

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; POLITEF;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTECHNOLOGY; BLOOD VESSEL GRAFT; BYPASS SURGERY; CATALYSIS; CONTROLLED STUDY; DEVICE; DOG; DRUG ACTIVITY; EXPLANT; FEMALE; HEPARINIZATION; IMMOBILIZATION; IN VIVO STUDY; NONHUMAN; POLITEF IMPLANT; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOSIS;

EID: 0037955987     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1909     Document Type: Article

References (35)

1. VEITH FJ. Femoral-popliteral-tibial occlusive disease. In: More WS, ed. Vascular Surgery - A Comprehensive Review. Philadelphia: W. B. Saunders Company, 1993; 27: 465-489.
2. VEITH FJ, GUPTA SK, ASCER E et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg 1986; 3: 104-114.
3. QUINONES-BALDRICH WJ, PREGO AA, UCELAY-GOMEZ R et al. Long-term results of infrainguinal revascularization with polytetrafluoroethylene: A ten-year experience. J Vasc Surg 1992; 16: 209-217.
4. CONSENSUS DOCUMENT. Chronic Critical Leg Ischaemia. Eur J Vasc Surg 1992; 6(Suppl. A): 1-28.
5. MONETA, GL, PORTER JM. Arterial substitutes in peripheral vascular surgery: a review. J Long-Term Eff Med Implants 1995; 5: 47-67.
6. LARM O, LARSSON R, OLSSON P. Surface-immobilized heparin. In: Lane DA, Lindahl U, Arnold E, eds. Heparin. London, 1988; 597-608.
7. HIRSH J, ANAND SS, HALPERIN JL, FUSTER V. AHA Scientific Statement. Guide to anticoagulant therapy: heparin. Circulation 2001; 103: 2994-3018.
8. LI-CHIEN HSU. Heparin-coating of bypass circuits. Perfusion 1991; 6: 209-219.
9. ANDERSON AB, CLAPPER DL. Coatings for blood-contacting devices. Med Plas Biomaterials 1998; 5: 18-26.
10. AL-LAMEE K, TAKTAK Y. New methods of surface modification and covalent attachment of heparin. Med Device Technology 1998; 24-27.
11. KIM SW, JACOBS H. Design of nonthrombogenic polymer surfaces for blood-contacting medical devices: Blood Purif 1996; 14: 357-372.
12. MATHEVE C. Clinical evidence of improved biocompatibility using heparin-coated surfaces. Perfusion 1996; 11: 264-269.
13. RIESENFELD J, OLSSON P, SANCHEZ J, MOLLNES TE. Surface modification with functionally active heparin. Med Device Technology 1995; 6: 24-31.
14. BOZDAYI M, BOROWIEC J, NILSSON L et al. Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery. Artif Organs 1996; 20: 1008-1016.
15. FUKUTOMI M, KOBAYASHI S, NIWAYA K et al. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment. Artif Organs 1996; 20: 767-776.
16. BOROWIEC J, THELIN S, BAGGE L et al. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. J Thoracic Cardiovasc Surg 1992; 104: 642-647.
17. KAUFMANN F, HENNIG E, LOEBE M et al. Improving the antithrombogenity of artificial surfaces through heparin coating - clinical experience with the pneumatic extracorporeal Berlin Heart assist device. Cardiovasc Engineering 1996; 1: 40-44.
18. SERRUYS PW, EMANUELSSON H, VAN DER GIESSEN W et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Circulation 1996; 93: 412-422.
19. SERRUYS PW, GRINES CL, STONE GW et al. Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting. Int J Cardiovasc Intervent 1998; 1: 19-27.
20. SERRUYS PW, VAN HOUT B, BONNIER H et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673-681.
21. DZAVIK V, CARERE RG, TEO KK et al. An open design, multicentre, randomized trial of percutaneous transluminal coronary angioplasty versus stenting, with a heparin-coated stent, of totally occluded coronary arteries: rationale, trial design and baseline patient characteristics. Can J Cardiol 1998; 14: 825-832.
22. LARSEN ML, ABILGAARD U, TEIEN AN, GJESDAL K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res 1978; 13: 285-288.
23. PASCHE B, ELGUE G, OLSSON P et al. A binding of antithrombin to immobilized heparin under varying flows conditions. Artif Organs 1991; 15: 481-491.
24. SOKAL RR, RHOLF FJ. Biometry, 2nd edn. New York: W. H. Freeman and Co., 1981; v-xviii: 1-859.
25. LEE ET. Statistical Methods for Survival Data Analysis, 2nd edn. New York: John Wiley & Sons, Inc., 1992; vii-xii: 1-482.
26. BOYCE B. Physical characteristics of expanded polytetrafluoroethylene grafts. Biol Synthet Vasc Prosthes 1982; 33: 553-561.
27. BERGQVIST D, JENSEN N, PERSSON NH. Heparinization of polytetrafluoroethylene (ePTFE) grafts. The effect on pseudointimal hyperplasia. Int Angiology 1988; 7: 65-69.
28. RITTER EF, KIM YB, REISCHL HP et al. Heparin coating of vascular prostheses reduces thromboemboli. Surg 1997; 122: 888-892.
29. DEVINE C, HONS BA, McCOLLUM C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass grafting: a multicenter trial. J Vasc Surg 2001; 33: 533-539.
30. BJORCK CG, BERGQVIST D, ESQUIVEL CO et al. Thrombin uptake and inhibition on heparinized polytetrafluoroethylene (PTFE) grafts and native sheep vessels. Thromb Res 1986; 42: 605-612.
31. KOCSIS JF, LLANOS G, HOLMER E. Heparin-coated stents. J Long-Term Eff Med Implants 2000; 10: 19-45.
32. ARNANDER C, BAGGER-SJOBACK D, FREBELIUS S et al. Long-term stability in vivo of a thromboresistant heparinized surface. Biomaterials 1987; 8: 496-499.
33. MOLLNES TE, VIDEM V, CHRISTIANSEN D et al. Platelet compatibility of an artificial surface modified with functionally active heparin. Thromb Haemost 1999; 82: 1132-1136.
34. SANCHEZ J, ELGUE G, RIESENFELD J, OLLSON P. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Research 1998; 89: 41-50.
35. VROMAN L. The life of an artificial device in contact with blood: initial events and their effect on its final state. Artif Device 1988; 64: 352-357.